Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Chemo Pharma Laboratories Ltd

CHEMOPH

Chemo Pharma Laboratories Ltd

CHEMOPH
Health CarePharmaceuticals
SmallcapWith a market cap of ₹19 cr, stock is ranked 4,181
High RiskStock is 4.82x as volatile as Nifty
125.869.78% (-13.65)
125.869.78% (-13.65)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹19 cr, stock is ranked 4,181
High RiskStock is 4.82x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹19 cr, stock is ranked 4,181
High RiskStock is 4.82x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
15.301.51—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.536.560.52%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Chemo Pharma Laboratories Limited is in negotiation to some other company and rehab to acquire business in power and chemicals. The Company was engaged in pharmaceuticals and bulk drugs business.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 17.54%, vs industry avg of 9.03%

Constant Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 41.94%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue0.495.611.110.821.000.670.790.301.841.88
Raw Materialssubtract0.000.000.000.000.000.000.000.000.000.18
Power & Fuel Costsubtract0.000.000.000.030.020.000.000.000.00
Employee Costsubtract0.030.060.130.210.150.090.140.070.02
Selling & Administrative Expensessubtract0.140.160.210.300.260.160.220.130.16
Operating & Other expensessubtract0.000.050.000.020.050.080.040.000.00
Depreciation/Amortizationsubtract0.000.000.000.000.020.020.020.010.01—
Interest & Other Itemssubtract0.000.000.000.000.000.000.000.010.00—
Taxes & Other Itemssubtract0.100.650.660.050.080.06-0.200.030.440.44
EPS1.4731.270.731.402.801.733.800.338.078.40
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2015

Annual report

PDF
FY 2016

Annual report

PDF
FY 2017

Annual report

PDF
FY 2018

Annual report

PDF
FY 2019

Annual report

PDF
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Chemo Pharma Laboratories Ltd15.931.51—
Sun Pharmaceutical Industries Ltd45.356.470.75%
Cipla Ltd28.514.380.89%
Torrent Pharmaceuticals Ltd68.4516.540.84%

Price Comparison

Compare CHEMOPH with any stock or ETF
Compare CHEMOPH with any stock or ETF
CHEMOPH
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding27.89%0.00%0.37%0.00%71.75%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

CHEMOPH has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Earnings
Chemo Pharma Laboratories standalone net profit rises 38.64% in the September 2024 quarter

Net profit of Chemo Pharma Laboratories rose 38.64% to Rs 0.61 crore in the quarter ended September 2024 as against Rs 0.44 crore during the previous quarter ended September 2023. There were no Sales reported in the quarter ended September 2024 and during the previous quarter ended September 2023.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Chemo Pharma Laboratories to announce Quarterly Result

Chemo Pharma Laboratories will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Chemo Pharma Laboratories AGM scheduled

Chemo Pharma Laboratories announced that the 82th Annual General Meeting (AGM) of the company will be held on 23 September 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Chemo Pharma Laboratories standalone net profit declines 34.21% in the June 2024 quarter

4 months agoBusiness Standard
Earnings
Chemo Pharma Laboratories standalone net profit declines 34.21% in the June 2024 quarter

Net profit of Chemo Pharma Laboratories declined 34.21% to Rs 0.25 crore in the quarter ended June 2024 as against Rs 0.38 crore during the previous quarter ended June 2023. There were no Sales reported in the quarter ended June 2024 and during the previous quarter ended June 2023.Powered by Capital Market - Live

4 months agoCapital Market - Live

Chemo Pharma Laboratories standalone net profit rises 10.00% in the September 2021 quarter

3 years agoBusiness Standard

Chemo Pharma Laboratories standalone net profit declines 62.50% in the June 2021 quarter

3 years agoBusiness Standard

Chemo Pharma Laboratories reports standalone net profit of Rs 0.02 crore in the March 2021 quarter

3 years agoBusiness Standard

Chemo Pharma Laboratories standalone net profit declines 42.86% in the December 2020 quarter

3 years agoBusiness Standard

BRIEF-Chemo Pharma Laboratories To Consider & Appoint Bhavin Sheth As CEO - Investing.com India

3 years agoInvesting.com